Plant Name: Cinnamomum aromaticum
Taxonomic Information:
Plant ID: NPO8255
Plant Latin Name: Cinnamomum aromaticum
Taxonomy Genus: Cinnamomum
Taxonomy Family: Lauraceae
Plant External Links:
NCBI TaxonomyDB:
119260
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Indonesia; India; Vietnam; Laos; Sri Lanka; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; KampoGeographical Distribution:
Indonesia; India; Vietnam; Laos; Sri Lanka; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ALPL; PGD; USP2; BRCA1; | |
| BCL2; | |
| MAPK1; | |
| CA2; CA14; CA7; | |
| CASP1; CASP7; | |
| TP53; NFKB1; | |
| KMT2A; | |
| HTT; RAB9A; NPC1; LMNA; FABP4; MAPT; HBB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 8.532E-08 | 2.322E-04 | BCL2, CA2, FABP4, KMT2A, MAPK1, NPC1, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.407E-07 | 3.275E-04 | CA14, CA2, CA7, HBB |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.593E-07 | 7.874E-04 | CA14, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.521E-06 | 2.644E-03 | ALPL, BRCA1, CASP7, MAPK1, NFKB1, NPC1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 3.101E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.410E-06 | 3.465E-03 | BCL2, MAPT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 6.936E-06 | 4.167E-03 | BRCA1, CASP7, MAPK1, NFKB1, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 7.436E-06 | 4.167E-03 | BCL2, HTT, LMNA, MAPT, TP53 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 7.464E-06 | 4.167E-03 | BCL2, BRCA1, HTT, LMNA |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 4.595E-03 | CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.159E-05 | 5.587E-03 | BCL2, CASP1, HTT, KMT2A, MAPK1, MAPT, NFKB1, RAB9A, TP53, USP2 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 1.364E-05 | 6.027E-03 | BCL2, CA2, CASP1, HTT, KMT2A, MAPK1, RAB9A, TP53 |
| BP | GO:0009987; cellular process | GO:0071356; cellular response to tumor necrosis factor | 1.413E-05 | 6.032E-03 | BRCA1, FABP4, MAPK1, NFKB1 |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 1.742E-05 | 7.293E-03 | BCL2, MAPK1, NFKB1 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 2.053E-05 | 8.127E-03 | BCL2, CA2, CA7, CASP1, CASP7, FABP4, HBB, HTT, KMT2A, LMNA, MAPK1, MAPT, NFKB1, PGD, RAB9A, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.213E-05 | 8.285E-03 | CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.311E-05 | 8.387E-03 | CYP2C9, CYP3A4, HBB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.282E-08 | 1.858E-06 | CASP7, LMNA, BCL2, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.637E-06 | 1.318E-04 | BCL2, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.831E-06 | 8.849E-05 | CASP7, CASP1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.194E-05 | 2.884E-04 | BCL2, MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.021E-06 | 7.403E-05 | CA2, CA7, CA14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.194E-05 | 2.884E-04 | BCL2, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.354E-05 | 4.685E-04 | BCL2, MAPK1, BRCA1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.585E-05 | 4.685E-04 | BCL2, MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.555E-05 | 5.504E-04 | BCL2, MAPK1, BRCA1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 3.823E-05 | 5.504E-04 | CASP7, CASP1, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05014 | Amyotrophic lateral sclerosis (ALS) | 3.044E-05 | 4.905E-04 | BCL2, CASP1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 5.481E-05 | 6.114E-04 | BCL2, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 6.611E-05 | 6.847E-04 | MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 4.257E-05 | 5.504E-04 | CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 8.936E-05 | 8.638E-04 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.244E-04 | 1.787E-03 | MAPK1, MAPT, TP53, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.342E-04 | 1.787E-03 | BCL2, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.455E-04 | 1.241E-03 | BCL2, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 3.012E-04 | 2.080E-03 | CASP7, MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.482E-04 | 1.799E-03 | BCL2, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 1.455E-04 | 1.241E-03 | CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 3.702E-04 | 2.440E-03 | BCL2, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 5.253E-04 | 3.127E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 5.606E-04 | 3.127E-03 | RAB9A, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.186E-03 | 5.719E-03 | BCL2, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.164E-03 | 5.719E-03 | CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.035E-03 | 5.558E-03 | CASP7, MAPK1, MAPT |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.223E-03 | 5.719E-03 | BCL2, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.757E-03 | 7.309E-03 | BCL2, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.683E-03 | 7.309E-03 | MAPK1, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.832E-03 | 7.381E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.263E-03 | 5.721E-03 | KMT2A, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.100E-03 | 5.695E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.043E-03 | 7.795E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.764E-03 | 7.309E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 5.493E-04 | 3.127E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.043E-03 | 7.795E-03 | FABP4, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.741E-03 | 9.243E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.116E-03 | 7.866E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 3.260E-03 | 9.789E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.909E-03 | 9.588E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 3.351E-03 | 9.789E-03 | MAPK1, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.741E-03 | 9.243E-03 | CYP2C9, CYP3A4 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 3.443E-03 | 9.789E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 2.659E-03 | 9.243E-03 | CASP1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 2.741E-03 | 9.243E-03 | MAPK1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.083E-03 | 9.789E-03 | CYP2C9, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 3.443E-03 | 9.789E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.260E-03 | 9.789E-03 | CA2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.493E-04 | 3.127E-03 | CYP2C9, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.443E-03 | 9.789E-03 | CYP2C9, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MAPK1; TP53; BCL2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
